Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
A phase 1/2 trial of Glecirasib, Sitneprotafib in non-small-cell lung cancer and small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.
Overview
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation is a phase 1/2 interventional study registered as NCT05288205 by Allist Pharmaceuticals, Inc., with 240 participants planned, started 2022-04-14 and due to reach its primary completion in 2027-03. Interventions recorded: JAB-21822, JAB-3312. Conditions listed: KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Shares Sitneprotafib, Glecirasib, Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer.
- TrialA Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Shares Glecirasib, Shanghai Allist Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Shares Glecirasib, Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer.
- TrialJAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Shares Glecirasib, Shanghai Allist Pharmaceuticals, Colorectal cancer.
- TrialA Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
- TrialA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
Shares Glecirasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Shares Shanghai Allist Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialTo Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Shares Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer.